KOL Bulletin: Next-Generation TYK2 Inhibitors Outperform Sotyktu in Psoriasis Trials but Fall Short of Biologics

on

Alumis' envudeucitinib, an oral TYK2 inhibitor, showed superior efficacy over apremilast in ONWARD1 and ONWARD2 phase 3 trials for moderate to severe plaque psoriasis, with high skin clearance rates and rapid onset; NDA planned for H2 2026.1

Takeda's zasocitinib, a highly selective next-gen TYK2 inhibitor, succeeded in two phase 3 trials for plaque psoriasis, outperforming Bristol Myers Squibb's Sotyktu (deucravacitinib), with FDA filing planned starting FY 2026.34

These next-generation TYK2 inhibitors demonstrate strong oral therapy results, eroding the divide with biologics, though not yet matching top biologic efficacy levels.6

Additional TYK2 developments include soficitinib's phase 2 success in atopic dermatitis and zasocitinib's promise in psoriatic arthritis.28

Sources:

1. https://www.dermatologytimes.com/view/phase-3-data-support-oral-tyk2-inhibitor-envudeucitinib-for-psoriasis

2. https://www.dermatologytimes.com/view/phase-2-tyk2-inhibition-shows-promise-in-ad

3. https://www.takeda.com/newsroom/newsreleases/2025/takeda-zasocitinib-phase-3-plaque-psoriasis-data-once-daily-pill/

4. https://www.fiercebiotech.com/biotech/takeda-looks-2026-fda-filing-its-sotyktu-rival-zasocitinib-after-phase-3-success

6. https://pubmed.ncbi.nlm.nih.gov/41577058/

8. https://www.barchart.com/story/news/37185163/psoriatic-arthritis-market-outlook-2034-7mm-epidemiology-30-key-companies-and-next-gen-il-17-tyk2-therapies-uncovered-by-delveinsight